Item request has been placed!
×
Item request cannot be made.
×
Processing Request
Prevention of congenital chagas disease by trypanocide treatment in women of reproductive age: A meta-analysis of observational studies.
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- Additional Information
- Source:
Publisher: Public Library of Science Country of Publication: United States NLM ID: 101291488 Publication Model: eCollection Cited Medium: Internet ISSN: 1935-2735 (Electronic) Linking ISSN: 19352727 NLM ISO Abbreviation: PLoS Negl Trop Dis Subsets: MEDLINE
- Publication Information:
Original Publication: San Francisco, CA : Public Library of Science
- Subject Terms:
- Abstract:
Background: Maternal-foetal transmission of Chagas disease (CD) affects newborns worldwide. Although Benznidazole and Nifurtimox therapies are the standard treatments, their use during pregnancy is contra-indicated. The effectiveness of trypanocidal medications in preventing congenital Chagas Disease (cCD) in the offsprings of women diagnosed with CD was highly suggested by other studies.
Methods: We performed a systematic review and meta-analysis of studies evaluating the effectiveness of treatment for CD in women of childbearing age and reporting frequencies of cCD in their children. PubMed, Scopus, Web of Science, Cochrane Library, and LILACS databases were systematically searched. Statistical analysis was performed using Rstudio 4.2 using DerSimonian and Laird random-effects models. Heterogeneity was examined with the Cochran Q test and I2 statistics. A p-value of <0.05 was considered statistically significant.
Results: Six studies were included, comprising 744 children, of whom 286 (38.4%) were born from women previously treated with Benznidazole or Nifurtimox, trypanocidal agents. The primary outcome of the proportion of children who were seropositive for cCD, confirmed by serology, was signigicantly lower among women who were previously treated with no congenital transmission registered (OR 0.05; 95% Cl 0.01-0.27; p = 0.000432; I2 = 0%). In women previously treated with trypanocidal drugs, the pooled prevalence of cCD was 0.0% (95% Cl 0-0.91%; I2 = 0%), our meta-analysis confirms the excellent effectiveness of this treatment. The prevalence of adverse events in women previously treated with antitrypanocidal therapies was 14.01% (95% CI 1.87-26.14%; I2 = 80%), Benznidazole had a higher incidence of side effects than Nifurtimox (76% vs 24%).
Conclusion: The use of trypanocidal therapy in women at reproductive age with CD is an effective strategy for the prevention of cCD, with a complete elimination of congenital transmission of Trypanosoma cruzi in treated vs untreated infected women.
Competing Interests: The authors have declared that no competing interests exist.
(Copyright: © 2024 Moraes et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
- References:
Rev Soc Bras Med Trop. 2020;53:e20190560. (PMID: 32348431)
Clin Microbiol Rev. 2022 Apr 20;35(2):e0015221. (PMID: 35239422)
Wkly Epidemiol Rec. 2015 Feb 6;90(6):33-43. (PMID: 25671846)
Med Anthropol. 2021 Aug-Sep;40(6):557-571. (PMID: 34047630)
Biol Res. 2010;43(3):307-16. (PMID: 21249302)
Enferm Infecc Microbiol Clin (Engl Ed). 2021 Nov;39(9):458-470. (PMID: 34736749)
J Pediatric Infect Dis Soc. 2016 Dec;5(4):e28-e31. (PMID: 27466398)
J Vector Ecol. 2023 Dec;48(2):66-71. (PMID: 37843448)
BMJ. 2003 Sep 6;327(7414):557-60. (PMID: 12958120)
PLoS Negl Trop Dis. 2016 Nov 7;10(11):e0005033. (PMID: 27820837)
Control Clin Trials. 1986 Sep;7(3):177-88. (PMID: 3802833)
Mem Inst Oswaldo Cruz. 2015 Jun;110(4):507-9. (PMID: 25993401)
Am J Trop Med Hyg. 2018 Feb;98(2):478-485. (PMID: 29210352)
Lancet. 2018 Jan 6;391(10115):82-94. (PMID: 28673423)
Trop Med Infect Dis. 2023 Aug 22;8(9):. (PMID: 37755884)
Clin Res Cardiol. 2014 Jan;103(1):1-10. (PMID: 23989652)
PLoS Negl Trop Dis. 2014 Nov 20;8(11):e3312. (PMID: 25411847)
Acta Trop. 2024 Jan;249:107059. (PMID: 37918504)
BMJ Glob Health. 2018 Oct 11;3(5):e001069. (PMID: 30364393)
J Infect Dis. 2017 May 1;215(9):1452-1458. (PMID: 28201741)
Front Microbiol. 2019 Jun 07;10:1250. (PMID: 31231337)
Infect Dis Poverty. 2023 Oct 16;12(1):95. (PMID: 37845734)
BMJ. 2021 Mar 29;372:n71. (PMID: 33782057)
Pediatr Rev. 2023 Apr 1;44(4):213-221. (PMID: 37002357)
PLoS Negl Trop Dis. 2019 Oct 24;13(10):e0007694. (PMID: 31647811)
Medicina (B Aires). 2019;79(2):81-89. (PMID: 31048272)
Med Sante Trop. 2019 Feb 1;29(1):26-27. (PMID: 31031240)
Trop Med Int Health. 2014 Aug;19(8):943-57. (PMID: 24815954)
J Infect Dis. 2004 Apr 1;189(7):1274-81. (PMID: 15031797)
Expert Rev Anti Infect Ther. 2010 Aug;8(8):945-56. (PMID: 20695749)
Acta Trop. 2017 Oct;174:149-152. (PMID: 28720492)
BMC Med Res Methodol. 2014 Feb 18;14:25. (PMID: 24548571)
Acta Trop. 2010 Jul-Aug;115(1-2):14-21. (PMID: 19932071)
Front Microbiol. 2019 Aug 14;10:1854. (PMID: 31474955)
Mem Inst Oswaldo Cruz. 2015 May;110(3):363-8. (PMID: 25760448)
PLoS Negl Trop Dis. 2017 Sep 11;11(9):e0005783. (PMID: 28892479)
Acta Trop. 2015 Nov;151:103-15. (PMID: 26293886)
Int J Mol Sci. 2023 Sep 07;24(18):. (PMID: 37762080)
Trop Med Int Health. 2023 Dec;28(12):912-922. (PMID: 37905331)
Int J Gynaecol Obstet. 2024 Mar;164(3):835-842. (PMID: 37493222)
Rev Soc Bras Med Trop. 2009 Sep-Oct;42(5):484-7. (PMID: 19967227)
BJOG. 2014 Jan;121(1):22-33. (PMID: 23924273)
- Accession Number:
0 (Trypanocidal Agents)
YC42NRJ1ZD (benzonidazole)
M84I3K7C2O (Nifurtimox)
0 (Nitroimidazoles)
- Publication Date:
Date Created: 20240905 Date Completed: 20240905 Latest Revision: 20240918
- Publication Date:
20240918
- Accession Number:
PMC11376591
- Accession Number:
10.1371/journal.pntd.0012407
- Accession Number:
39236037
No Comments.